Receipt Of JNCI Designation For KT-939
Release time：2025-06-25 14:00
Suzhou, 25 June, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that its in-house developed KT-939 has passed the review of the Japanese Nomenclature Cosmetic Ingredient (the “JNCI”) by the Japanese Cosmetic Industry Committee. The officially assigned name is メチルオキセタンカルバミドチアゾリルレゾルシノ一ル. Such designation approval signifies that KT-939 may commence application and sales as a cosmetic raw material in Japan market, laying a material foundation for the Company’s expansion in the functional cosmetic raw material market, helping further promote the demand for products of the Company and driving the company to become a leading supplier of the functional cosmetic raw material.
KT-939 is a tyrosinase inhibitor developed by the Company, effectively inhibiting melanin production with antioxidant and anti-inflammatory effects, which can be safely used when applied to human skin while effectively demonstrating the whitening and freckle-removing effects. Previous studies of the Company show that KT-939 has the strongest tyrosinase inhibitory activity reported to date. In the human cells tyrosinase inhibitory activity experiment, cell melanin production experiment and protein binding experiment, KT-939 is significantly superior to cosmetic compounds with the same target, including Thiamidol, Butylresorcinol (“577”), Phenylethyl resorcinol (“377”), arbutin, hydroquinone and kojic acid, etc. In addition, the Company has completed related necessary safety evaluation in accordance with the requirements of the Safety and Technical Standards for Cosmetics (2015 Edition) in China. The data shows that the safety profile of KT-939 is also more favorable than that of the foregoing compounds.
Dr. Youzhi Tong, the founder, chairman and CEO of Kintor Pharma, said,"Along with continuous expansion of the global cosmetic market scale as well as the increasing penetration rate of functional products in the cosmetics market, cosmetic brands’ need for the quantity and quality of functional raw material both increase. The potential for the functional cosmetic raw materials market is huge. Strategic layout for cosmetic raw material business will provide a key support for the Company’s transformation and upgrade."
recommend News
2025-06-25
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn